- Home
- NAGE vs PACB Comparison
NAGE vs PACB Comparison
Compare NAGE & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | PACB |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 459.0M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NAGE | PACB |
|---|---|---|
| Price | $4.86 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.00 | $2.10 |
| AVG Volume (30 Days) | 1.1M | ★ 5.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $20.75 | $11.22 |
| Revenue Next Year | $19.96 | $12.41 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $4.73 | $0.85 |
| 52 Week High | $14.66 | $2.73 |
Technical Indicators
Market Signals| Indicator | NAGE | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 32.36 |
| Support Level | $4.73 | $1.18 |
| Resistance Level | $5.32 | $1.37 |
| Average True Range (ATR) | 0.28 | 0.10 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 11.37 | 6.25 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.